[Revised January 24, 2026]

Top 10 Global Thought Leaders in Pharma: Key Speakers and Influencers

Introduction: This report profiles ten of the most prominent public speakers and thought leaders in the pharmaceutical industry today. These individuals – spanning industry executives, pioneering scientists, regulatory leaders, and health advocates – are shaping conversations around drug development, innovation, policy, and patient outcomes. Each section below details a leader’s professional background, their common speaking topics, notable speaking engagements, and highlights of their influence on the pharma and biotech field. Relevant quotes and citations are provided to illustrate their messages and impact.

1. Albert Bourla – CEO of Pfizer

Albert Bourla, Pfizer’s CEO, speaking at a biotech summit in 2023. Background: Dr. Albert Bourla has over 30 years of experience at Pfizer, rising through R&D and commercial roles to become CEO in 2019 ^[1]. He led Pfizer during the COVID-19 pandemic, overseeing the rapid development of the Pfizer-BioNTech mRNA vaccine. Bourla’s leadership and collaboration with BioNTech’s team (under Dr. Uğur Şahin) resulted in one of the first globally authorized COVID vaccines, a milestone for which he and BioNTech’s founders received recognition such as the Atlantic Council’s Distinguished Business Leadership Award ^{[2] [3]}.

Speaking Topics: As a speaker, Bourla often emphasizes innovation through partnership, scientific collaboration, and global health equity. He has highlighted that the toughest healthcare challenges “require world-class collaboration to fuel game-changing innovation,” especially between big pharma and biotech startups ^[4]. Bourla also speaks about lessons from the pandemic – from combating vaccine misinformation to improving global access. For instance, at the 2022 World Economic Forum, he underscored improving affordability of medicines, clarifying Pfizer’s goal “to cut the number of people who couldn’t afford Pfizer’s medicines by 50%” ^[5]. In a 2023 APEC CEO Summit address, he urged business leaders to help “cure” the “epidemic of exclusion” – be it economic, social or personal exclusion – through inclusive culture and partnerships ^{[6] [7]}. This theme of business responsibility in public health resonates in his speeches.

Notable Engagements: Bourla is a sought-after keynote speaker at major industry and policy forums. He has delivered keynotes at events like the APEC CEO Summit 2023 and the Los Angeles Bioscience Ecosystem Summit (LABEST) 2023^[8]. He also frequently appears in high-profile interviews (e.g. Face the Nation, Davos panels) to discuss the future of vaccines and pandemic preparedness. At the J.P. Morgan Healthcare Conference 2026, Bourla outlined Pfizer's strategic pivot from COVID-era volatility toward pipeline execution and strategic acquisitions ^[9].

Influence: Under Bourla's leadership, Pfizer not only delivered a historic vaccine but has continued to drive innovation through major acquisitions. In late 2025, Pfizer completed its $10 billion acquisition of Metsera, transforming its obesity strategy with monthly injectables and oral combination therapies ^[10]. Bourla projects the obesity market will reach $150 billion by 2030 and has positioned Pfizer to compete aggressively in this space. Amid shifting U.S. vaccine policy under the current administration, Bourla has remained steadfast in defending vaccine science, stating that concerns raised by officials "don't have merit" and would not change Pfizer's long-term investments in vaccines ^[11]. His messages about partnership and inclusion position him as a thought leader championing collaborative innovation.

Notable Quote: “Exclusion is an epidemic. Business must be a part of the cure. And like any new medicine, this cure requires purposeful partnerships to develop.” ^[7]

2. Stéphane Bancel – CEO of Moderna

Stéphane Bancel, CEO of Moderna, speaking on the biotech industry’s future. Background: Stéphane Bancel has served as CEO of Moderna since 2011, transforming a small startup into a leading mRNA biotech. Under his leadership, Moderna developed a breakthrough COVID-19 vaccine in 2020, validating mRNA vaccine technology ^[12]. Bancel’s background includes prior executive roles at BioMérieux and Eli Lilly, and he is also a partner at the venture firm Flagship Pioneering ^{[13] [14]}. His experience straddles pharma, diagnostics, and biotechnology, giving him broad perspective on healthcare innovation.

Speaking Topics: Bancel is known for his enthusiasm about mRNA technology and the future of vaccine development. In public forums, he often discusses how mRNA can be applied beyond COVID-19 – for flu, RSV, cancer therapies, etc. – and how Moderna is “much more than a COVID company.” For example, he has highlighted that Moderna’s pipeline spans vaccines for multiple diseases and even personalized cancer vaccines ^[15]. Bancel also addresses the challenges of scaling innovation: at industry conferences like JPMorgan Healthcare and SXSW, he has spoken about Moderna’s journey from a novel idea to a commercial powerhouse, and the need to maintain scientific agility even as the company grows ^[16]. Another key topic is pandemic preparedness and equitable vaccine access. In early 2023, Bancel testified to the U.S. Senate to explain Moderna’s COVID vaccine pricing, where he noted factors like loss of economies of scale and projected a 90% drop in demand post-pandemic ^[17]. This reflects his engagement in discussions on vaccine economics and policy.

Notable Engagements: Bancel remains a fixture on the global speaking circuit. At the 44th Annual J.P. Morgan Healthcare Conference in January 2026, he outlined Moderna's strategic repositioning following the steep decline in COVID-19 vaccine demand, emphasizing cost discipline and late-stage pipeline programs ^[18]. At the World Economic Forum in Davos (January 2026), Bancel made headlines by announcing that Moderna will not invest in new late-stage vaccine trials in the U.S. due to growing vaccine skepticism from U.S. officials, stating "You cannot make a return on investment if you don't have access to the US market" ^[19]. He also delivered a commencement address in 2023 at the University of Minnesota, where he stressed making the world a better place through science ^[20].

Influence: Bancel has navigated Moderna through significant challenges since the pandemic's peak. In 2025, the company implemented a 10% workforce reduction, withdrew its flu/COVID combination vaccine application, and discontinued three mRNA vaccine programs. Yet Moderna's mNEXSPIKE COVID vaccine (FDA approved May 2025) became the firm's top U.S. seller, accounting for 24% of all COVID vaccinations ^[21]. The company ended 2025 with approximately $8.1 billion in cash and expects to reach cash breakeven by 2028. Bancel continues advancing Moderna's oncology pipeline, including intismeran autogene (mRNA-4157) for melanoma, co-developed with Merck. His speeches now blend technical vision with frank assessments of the regulatory and political landscape affecting vaccine development ^[22].

Notable Quote: “We’ve been expecting a 90% reduction in demand… As you can see, we’re losing economies of scale.” ^[17] (Explaining the post-pandemic vaccine market and Moderna’s pricing considerations.)

3. Pascal Soriot – CEO of AstraZeneca

Background: Sir Pascal Soriot has been Chief Executive Officer of AstraZeneca since 2012, steering the UK-based pharma giant through a remarkable period of innovation and growth. A veterinarian-turned-executive, Soriot previously held top posts at Roche and Genentech. At AstraZeneca, he refocused the company on cutting-edge science (especially in oncology and immunotherapy) and famously partnered with Oxford University in 2020 to develop a widely distributed COVID-19 vaccine. Soriot was knighted in 2022 for services to life sciences, highlighting his contributions to the industry ^[23].

Speaking Topics: Pascal Soriot speaks frequently about global health responsibility, scientific collaboration, and sustainability in pharma. During the pandemic, he took a principled stand to distribute AstraZeneca’s COVID-19 vaccine on a not-for-profit basis during the emergency. “We decided to provide it at no profit, because our top priority was to protect global health,” Soriot has explained ^[24]. He often addresses equitable access to medicines, citing AstraZeneca’s tiered pricing and extensive supply to low-income countries (over 250 million doses to COVAX by end of 2021) ^{[25] [26]}. Beyond the pandemic, Soriot’s speeches emphasize innovation through partnership – for example, how academia-industry collaborations (like AZ’s with Oxford) can accelerate R&D. He also acknowledges challenges such as climate change: calling it “the biggest threat against humanity,” he has advocated industry action on sustainability while developing new medicines ^[27]. Internally, Soriot champions a science-driven culture, pushing AstraZeneca to “follow the science” in pursuing novel drug targets and technologies.

Notable Engagements: Soriot engages with both policy makers and scientific audiences. He has spoken at the World Economic Forum and high-level climate forums, underlining that pharma must be part of global solutions. At the 2025 American Society of Clinical Oncology (ASCO) annual meeting, Soriot discussed AstraZeneca's oncology presentations and navigated questions about the Trump administration's drug pricing initiatives ^[28]. In 2025, Soriot made headlines with frank assessments of European competitiveness, stating "Europe is losing ground. They're focused more on social benefits and managing costs" ^[29]. Reports also indicate he has been considering a potential move of AstraZeneca's primary stock listing from London to the U.S. ^[30].

Influence: In July 2025, Soriot announced AstraZeneca's $4 billion manufacturing facility in Virginia—the company's largest-ever single manufacturing investment—as part of a $50 billion commitment to new U.S. facilities by 2030^[29]. The Virginia facility will manufacture weight-management drugs including oral GLP-1s, positioning AstraZeneca in the competitive obesity market. In November 2025, Soriot personally negotiated a drug pricing deal with the U.S. administration ^[31]. As the highest-paid CEO among major European pharmaceutical companies (earning $21.3 million in 2023), Soriot continues to influence both the strategic direction of big pharma and its social responsibilities. His seven-year streak of leading AstraZeneca's oncology presentations at ASCO reflects the company's dominance in cancer research ^[28].

Notable Quote: “We decided to do it at no profit... Despite the criticism, I absolutely don’t regret it. We’ve saved millions of hospitalisations. The team continues to do a stellar job.” ^[32]

4. Dame Emma Walmsley – Former CEO of GSK

Background: Dame Emma Walmsley served as Chief Executive Officer of GlaxoSmithKline (GSK) from 2017 until December 31, 2025, making her notably the first woman to lead a top-10 global pharmaceutical company ^[33]. With a background in consumer products and pharmaceuticals, Walmsley led GSK through a strategic refocus on biopharma innovation, including spinning off its consumer health division (Haleon). She championed investments in vaccines (e.g. the world's first approved malaria vaccine and a new RSV vaccine) and in emerging technologies like artificial intelligence to boost drug discovery ^[34]. Walmsley was made Dame (DBE) in 2020 for services to the pharmaceutical industry.

Speaking Topics: Emma Walmsley frequently addresses innovation, health access, and the intersection of technology and healthcare. In interviews and forums, she underscores the paradox that “We’ve extended our lifespan, but not our healthspan,” calling for more focus on healthy life years ^[35]. A strong advocate of prevention, Walmsley often highlights the high return on investment in vaccines: “There is no better return on investment in healthcare than vaccination, apart from clean water,” she noted, emphasizing vaccines’ role in reducing healthcare costs and improving productivity ^[36]. She is also bullish on digital and data science in pharma – Walmsley has described how GSK is leveraging AI/machine learning to accelerate R&D (from target identification to clinical trial design) ^{[34] [37]}. At a Columbia University event in 2023, she detailed how new tech platforms like mRNA, gene therapy, and AI are “making waves” in developing treatments for previously untreatable diseases ^[38]. As a leader, Walmsley addresses cultural change and diversity too: she often speaks about empowering talent and has become a role model for women in STEM leadership.

Notable Engagements: Throughout her tenure, Walmsley was a familiar presence at global business forums and academic venues. She spoke at the FT Global Pharma and Biotech Summit, the World Economic Forum, and was featured in Columbia Business School's Distinguished Speaker Series ^[35]. In these talks, she shared strategic insights on the pharma landscape – discussing how incentives in healthcare need realignment toward prevention and outcomes ^[39]. In her final quarters as CEO, she stated: "GSK's momentum continues with another quarter of strong performance, supporting upgraded guidance for 2025, and positioning us well for 2026" ^[40].

Influence: As the first female CEO of a top-10 pharma company, Emma Walmsley's impact extends far beyond GSK. During her tenure, she reframed GSK's strategy around science and tech, investing in AI partnerships and genetic research. Under her leadership, GSK nearly doubled its sales in oncology and announced $30 billion in U.S. R&D and supply chain investments over five years (September 2025), including a $1.2 billion factory in Pennsylvania ^[41]. Walmsley stepped down on December 31, 2025, succeeded by Luke Miels, though she remains with the company through September 2026 in a transition support role. As she stated, "2026 is a pivotal year for GSK to define its path for the decade ahead, and I believe the right moment for new leadership" ^[42]. She leaves behind 15 major pipeline opportunities set to launch between 2025 and 2031, with projected total sales exceeding £40 billion ($54.8 billion) by 2031.

Notable Quote: “It’s better for everybody to stop the disease… There is no better return on investment in healthcare than vaccination, apart from clean water.” ^[36]

5. Vas Narasimhan – CEO of Novartis

Vas Narasimhan, Novartis CEO, discussing AI’s role in drug development. Background: Dr. Vasant “Vas” Narasimhan, a physician by training, has been the Chief Executive Officer of Novartis since 2018 ^[43]. He has steered Novartis to reinvent itself as a “medicines company powered by data and digital,” reflecting his strong emphasis on technological transformation. Narasimhan joined Novartis in 2005 and held roles in development and strategy, including Global Head of Drug Development. As CEO, he has led initiatives in cell/gene therapies, launched an “AI innovation lab” in partnership with tech firms, and fostered a culture he calls “unbossed” – empowering teams and flattening hierarchy to spur innovation.

Speaking Topics: Vas Narasimhan is a prominent voice on digital innovation, AI in healthcare, advanced therapies, and leadership in pharma. He often discusses how emerging technologies will reshape drug discovery and development. “There’s no question that AI is going to reshape… the healthcare industry,” he noted, explaining that AI can make research and operations “much more efficient, much more productive and unlock resources… to find new medicines \ [and] deliver those medicines better” ^[44]. At venues like the World Economic Forum and JPMorgan conferences, Narasimhan has shared his vision of AI accelerating clinical trials, improving diagnostic accuracy, and personalizing treatments ^{[45] [46]}. In addition, he speaks about next-generation platforms (such as cell/gene therapy and RNA therapeutics), highlighting that we are seeing an explosion of biotech innovation “that will have a lasting impact” on disease management ^[47]. Another recurring theme is climate change and global health – Narasimhan is one of few pharma CEOs to link climate to health outcomes, warning that changing climates can spread diseases and stressing cross-sector efforts to prepare healthcare systems ^[48]. As a leader, he also shares insights on organizational culture, often citing how leadership and talent development are crucial in navigating a rapidly changing industry.

Notable Engagements: Narasimhan regularly contributes at high-profile forums. He was named to the 2025 TIME100 Health list, recognizing him among the 100 most influential people driving the future of global health ^[49]. At the J.P. Morgan Healthcare Conference 2026 and World Economic Forum in Davos, he discussed Novartis's growth trajectory, stating the company expects to "not really" be exposed to tariffs by mid-2026 due to an agreement with the U.S. government ^[50]. In a podcast with Nicolai Tangen (Norges Bank Investment Management), Narasimhan discussed his leadership philosophy of being the "chief energy officer" and shared insights on AI partnerships, cell and gene therapies, and Novartis's transformation from a sprawling conglomerate to a focused medicines company nbim.no.

Influence: In October 2025, Narasimhan announced Novartis's $12 billion acquisition of Avidity Biosciences—the company's biggest deal in a decade—as part of a buying spree of more than 35 companies over the past year ^[51]. Novartis projects 5-6% compound annual sales growth (CAGR) from 2025-2030, backed by 30+ potential high-value pipeline assets, and achieved a 41.2% core operating income margin in the first nine months of 2025—two years ahead of plan ^[52]. Narasimhan's $23 billion U.S. manufacturing investment announced in December 2025 serves as a moat against tariff concerns. His advocacy for using AI and data to accelerate cures, combined with his progressive stance on climate-health interlinkages, positions him as an influential voice pushing pharma to embrace innovation both scientifically and socially.

Notable Quote: “AI can make us much more efficient, much more productive and unlock resources… to find new medicines, deliver those medicines better and ultimately impact healthcare positively.” ^[53]

6. Uğur Şahin – CEO of BioNTech

Background: Prof. Uğur Şahin is the co-founder and CEO of BioNTech, and a physician-scientist known for his work in immunotherapy and vaccines. Şahin and his wife Dr. Özlem Türeci founded BioNTech in 2008 with the aim of developing personalized cancer therapies. Pre-pandemic, his team was already pioneering mRNA-based cancer vaccines. In 2020, Şahin initiated “Project Lightspeed”, pivoting BioNTech’s mRNA platform to develop a COVID-19 vaccine in record time ^[54]. The success of the Pfizer-BioNTech vaccine turned Şahin into one of the world’s most influential biotech leaders. He has received numerous accolades, and with Türeci was named among Time’s 100 Most Influential People for their vaccine work.

Speaking Topics: Uğur Şahin is somewhat soft-spoken, but when he speaks publicly it is often about the frontier of medical science – especially mRNA technology – and its potential to fight diseases like cancer. He is passionate about the idea that the mRNA vaccine approach used for COVID-19 can be “repurposed so that it primes the immune system to attack cancer cells” ^[55]. In interviews, Şahin expresses optimism that cancer vaccines could become a reality by the end of this decade, predicting they could be available “before 2030” ^[56]. He frequently explains the science in accessible terms: how mRNA vaccines work like “wanted posters” training the immune system ^[57], and how similar principles apply to identifying tumor antigens. Another focus area is scientific collaboration and speed. Şahin often credits the global partnership (with Pfizer and others) that enabled their COVID vaccine to succeed so fast ^[58]. He advocates maintaining that collaborative spirit for other global health problems. Additionally, Şahin speaks about pandemic preparedness and the need for rapid-response platforms; he has engaged in discussions with governments on how to respond even faster to future outbreaks by leveraging mRNA and other technologies investors.biontech.de.

Notable Engagements: Though not a frequent presence on the generic speakers' circuit, Şahin has delivered keynotes at major scientific conferences. In 2023, he was a closing plenary speaker at the International mRNA Health Conference, alongside Nobel laureates Karikó and Weissman mrnaconferenceszeged.hu. He has presented at the J.P. Morgan Healthcare Conference (2024) to outline BioNTech's strategic vision investors.biontech.de. In 2024, Şahin delivered the Crick Lecture at the Francis Crick Institute in London, discussing the future of mRNA technology crick.ac.uk. He also spoke at the University of Heidelberg's Climate Change and Pandemics conference as a keynote speaker. Şahin and Türeci gave a high-profile joint interview on BBC's Laura Kuenssberg show in late 2022, discussing cancer vaccines in depth ^[55].

Influence: In June 2025, BioNTech acquired CureVac for approximately $1.25 billion, consolidating its position as the leading mRNA company by absorbing a former COVID-19 vaccine rival ^[59]. This acquisition strengthens BioNTech's research, development, manufacturing, and commercialization of mRNA-based cancer immunotherapy. BioNTech announced in May 2024 that it expects to launch its first cancer therapies starting in 2026, with Şahin maintaining his prediction that mRNA cancer vaccines could be available "before 2030" ^[56]. The company is now developing mRNA-based vaccines for infectious diseases including COVID-19, malaria, tuberculosis, and mpox, while advancing combination therapies pairing CAR-T cell treatments with mRNA-based vaccines ^[60]. As a scientist-entrepreneur, Şahin exemplifies how cutting-edge research can directly translate into life-saving products, and he remains a guiding voice on the future of vaccines.

Notable Quote: “Asked when cancer vaccines based on mRNA might be ready… Prof Şahin said they could be available ‘before 2030.’” ^[56]

7. Katalin Karikó – mRNA Pioneer, Nobel Laureate

Background: Dr. Katalin Karikó is a biochemist whose relentless work over decades laid the foundation for mRNA therapeutics. A Hungarian-born scientist, Karikó spent much of her career at the University of Pennsylvania researching mRNA delivery. Despite setbacks and lack of funding (famously, she was once demoted at Penn), she persisted in refining the idea that mRNA could be engineered as a drug or vaccine. Her collaboration with Dr. Drew Weissman led to a 2005 breakthrough – modifying mRNA to avoid inflammatory reactions – a discovery crucial to mRNA vaccine success ^[61] frontiersofknowledgeawards-fbbva.es. In 2023, Karikó and Weissman were awarded the Nobel Prize in Medicine for this work. She is now an adjunct professor at University of Szeged and was previously a senior VP at BioNTech.

Speaking Topics: Katalin Karikó’s personal journey has made her an icon of scientific perseverance and innovation. In talks and interviews, she often shares her story to encourage young scientists. “Persistence can pay off, in the end,” she affirmed, reflecting on her career’s lesson ^[62]. A key theme is overcoming obstacles in research – Karikó emphasizes focusing on what one can change and not being discouraged by others’ success or skepticism ^{[63] [64]}. She also speaks about work-life balance in science, encouraging women researchers that one “doesn’t have to choose between having a family and a career,” noting how her own daughter watched her work hard and was inspired to high achievement ^{[65] [66]}. On the scientific front, Karikó explains the significance of mRNA technology in simple terms, recounting how incremental improvements (“sometimes incremental increase, sometimes big jump”) led to “optimal RNA suitable for therapy” ^[67]. She highlights the collaborative nature of breakthroughs – for example, in her Nobel Banquet speech she thanked the many colleagues whose work “built the foundation” for the mRNA vaccines ^[68]. Her humility and emphasis on team science are notable in her public remarks.

Notable Engagements: Post-Nobel, Karikó has been in high demand as a speaker. She delivered a formal Nobel Lecture in December 2023 (detailing the science of nucleoside-modified mRNA) and spoke at the Nobel Banquet, where her warmth and humor shone ^[69]. In May 2025, Karikó was elected to the U.S. National Academy of Sciences in recognition of her pioneering contributions to mRNA vaccine research. She also delivered the prestigious Mendel Lecture at the European Society of Human Genetics Annual Meeting, discussing clinical applications of mRNA therapeutics. Her autobiography "Breaking Through: My Life in Science" received the ASIMOV Prize in May 2025 ^[70]. During the 2025-2026 academic year, she delivered online presentations at universities in Africa, the United States, and met audiences in four European countries. At the Berlin Falling Walls Science Summit, participants "showered the stage with red roses" after her lecture u-szeged.hu. In May 2025, she visited Vienna and delivered a lecture at MedUni Vienna on the future of mRNA medicine meduniwien.ac.at.

Influence: Katalin Karikó, who turned 70 on January 17, 2025, continues to be a symbol of resilient innovation in pharma and biotech. Her life story – an immigrant scientist making a revolutionary contribution after years of rejection – has inspired countless researchers. Hungary celebrated its first female Nobel Prize-winning researcher with an exhibition and event at the University of Szeged, where she is currently teaching. In a notable moment of solidarity, Karikó was among the first to congratulate László Krasznahorkai, her former university contemporary who received the 2025 Nobel Prize in Literature – an exclusive photo captured their reunion at the Embassy of Sweden in Hungary u-szeged.hu. The mRNA platform she helped create is now being explored for vaccines against HIV, cancer, and more. By openly sharing credit and urging support for the "diligent fellow scientists" in the trenches ^[68], Karikó continues to influence a culture of collaboration and acknowledgement in pharma R&D.

Notable Quote: “But I suppose the message in all this is that persistence can pay off, in the end.” ^[62]

8. Dr. Scott Gottlieb – Former FDA Commissioner and Health Policy Leader

Background: Dr. Scott Gottlieb is a physician and public health expert who served as the 23rd Commissioner of the U.S. Food and Drug Administration (FDA) from 2017 to 2019 ^[71]. At FDA, he was known for advancing policies to streamline drug approvals and encourage innovation – his tenure saw record numbers of novel drug and device approvals. Gottlieb had earlier roles at FDA and the Centers for Medicare & Medicaid Services, and since leaving government he has become a prominent commentator on healthcare. He is a Resident Fellow at the American Enterprise Institute, a partner at NEA (a venture capital firm), and sits on boards of companies including Pfizer, Illumina, and TempusAI. In November 2025, UnitedHealth added Gottlieb to its board of directors, expanding his influence in the healthcare sector ^[72]. Dr. Gottlieb is also the author of "Uncontrolled Spread," a best-selling book analyzing the U.S. COVID-19 response.

Speaking Topics: Scott Gottlieb is a prolific speaker on a range of topics at the intersection of healthcare, policy, and technology. Regulatory innovation is a central theme: he frequently discusses how to modernize regulation to keep pace with science. Under his leadership, FDA rolled out new frameworks for gene therapies, cell therapies, and digital health devices ^[73], and he continues to speak about adapting regulatory pathways for advances like AI in drug development. In fact, Gottlieb has been “a primary voice” describing how AI tools will disrupt healthcare, advocating for clear regulatory guidelines to foster AI-driven therapeutics ^[74]. Another key topic is the economics of healthcare and access. He addresses questions like how to ensure patients have affordable access to innovations without bankrupting the system ^[75]. In speeches titled “The Landscape of Affordable Healthcare,” he explores sustainable models for drug pricing and insurance coverage ^[75]. Gottlieb also speaks on pandemic preparedness and lessons learned from COVID-19. He argues that public health must be viewed through a national security lens, outlining steps to improve future outbreak responses ^{[76] [77]}. Additionally, as a former regulator, he offers insider insights on policymaking – explaining how decisions are made in Washington and advising industry leaders on engaging with regulators ^[78].

Notable Engagements: Dr. Gottlieb remains in high demand on the conference circuit, bridging clinical, business, and policy perspectives. In February 2026, he will keynote AAM's Access! 2026 conference, participating in a fireside chat on the future of healthcare and evolving policy ^[79]. He will also speak at the 2026 NIC Spring Conference on healthcare policy ^[80]. In 2025, Gottlieb was named to the STAT STATUS List recognizing influential healthcare figures ^[81]. In September 2025, he spoke alongside former FDA colleagues on FDA innovation reform and rare disease policy at USC Schaeffer ^[82]. Gottlieb made waves by opposing Robert F. Kennedy Jr.'s nomination as Health Secretary, and in December 2025 expressed concern over the administration's pending overhaul of the childhood vaccine schedule, warning "If we go to the Danish model and we end vaccination...we're going to see them resurge and we're going to have to build new pediatric hospitals" ^[83].

Influence: Scott Gottlieb's unique blend of regulatory experience and communication skills has made him one of the most influential voices in pharma policy today. In a February 2025 JAMA article, he called for the FDA to return to older AI policies, noting that "recent changes to policies related to the regulation of AI have added new uncertainties" ^[84]. He has emphasized that improved use of AI in drug development is essential to keep ahead of rising biotech competition from China, stating "Our best lever for countering [China] is really going to be to think about how to modernize our regulatory framework" ^[82]. Gottlieb's perspectives continue to shape industry thinking on gene therapy, real-world evidence, and AI integration. Through his speeches, board positions, and media appearances, Dr. Gottlieb continues to shape the environment in which pharmaceutical innovation and regulation coexist.

Notable Quote: “What is the future of medical innovation and how will we unlock the promise of new technologies like gene therapy, digital health, artificial intelligence, and regenerative medicine?... What are the regulatory and reimbursement strategies we’ll need to adopt to make sure these innovations reach patients?” ^[85]

9. Dr. Peter Hotez – Vaccine Scientist and Advocate

Background: Dr. Peter J. Hotez is a physician-scientist who has dedicated his career to developing vaccines for neglected tropical diseases and to public science advocacy. Based in Texas, he is the Co-Director of the Texas Children’s Hospital Center for Vaccine Development and Dean of the National School of Tropical Medicine at Baylor College of Medicine ^[86]. Hotez has led efforts to create low-cost vaccines for diseases like hookworm and Chagas, and most recently co-developed “Corbevax,” an affordable, patent-free COVID-19 vaccine for low-income countries ^[87]. For this work, he and colleague Maria Elena Bottazzi were nominated for the 2022 Nobel Peace Prize ^[87]. Hotez is also well known for his outspoken defense of vaccines and science – he’s authored books on the rise of anti-vaccine sentiment and is a familiar figure in media countering misinformation.

Speaking Topics: Peter Hotez is a passionate speaker on global health equity, vaccine science, and combating misinformation. A core theme is the plight of “neglected” diseases and populations – he highlights how billions in the developing world lack access to vaccines and medicines that wealthy countries take for granted ^[88]. At the same time, Hotez underscores that misinformation in wealthy countries is causing resurgences of diseases: for example, he notes that false claims about vaccines have led to declining vaccination rates and the return of measles and other once-controlled illnesses ^{[89] [88]}. In numerous interviews and talks, Dr. Hotez has addressed the tactics of the anti-vaccine movement and urged that “misinformation \ [be] treated as a public health issue” (essentially a societal pathogen) ^{[90] [91]}. He emphasizes clear science communication as a remedy: “Communicating clear messages about the ongoing pandemic is of vital importance in an environment rife with confusing and misleading messages,” Hotez said, cautioning against extremes of alarmism or denial ^[92]. Another major topic for Hotez is vaccine diplomacy and access. He frequently points out that technologies like the COVID vaccines must reach everyone – he advocates for sharing know-how and scaling production in the Global South, exemplified by his team’s open-source Corbevax vaccine. Additionally, as a pediatrician and a parent of an adult daughter with autism, Hotez speaks from personal experience to debunk the myth linking vaccines to autism, bringing empathy to the conversation ^{[93] [94]}.

Notable Engagements: Dr. Hotez engages with both scientific audiences and the general public. On April 24, 2025, Yale School of Public Health Dean Megan L. Ranney presented the prestigious C.-E. A. Winslow Medal to Dr. Hotez, introducing him as "a great scientist, an ardent vaccine advocate, and science explainer" ^[95]. In January 2025, Hotez published a paper in PLOS Global Public Health titled "It won't end with COVID: Countering the next phase of American antivaccine activism 2025–29", discussing strategies to address vaccine resistance ^[96]. In September 2025, NPR featured Hotez in a segment on how he "takes the war against science very personally" ^[97]. On December 31, 2025, he appeared on Here & Now to discuss vaccine skepticism in the United States and his concerns about public health heading into 2026 ^[98]. Hotez was recognized in the U.S. News Best Leaders 2025 list ^[99].

Influence: In 2025, Hotez released his sixth book, "Science Under Siege", co-authored with climate scientist Michael E. Mann, examining the forces driving the anti-science movement – from fossil fuel industry supporters to social media conspiracy theorists ^[97]. His low-cost, patent-free Corbevax COVID-19 vaccine has now been administered to more than 100 million people in India and Indonesia ^[95]. His work over four decades has resulted in half a billion people receiving treatment for neglected tropical diseases. His concept of "science tikkun" – using science as a way to repair the world – encapsulates his broad humanistic approach ^[100]. Perhaps most importantly, through countless talks and media engagements, Dr. Hotez has helped maintain public trust in vaccines during a time of intense skepticism, positioning himself as an indispensable voice defending the integrity of biomedical science in the public sphere.

Notable Quote: “We’ve been hearing either the sky was falling or there was no problem… the reality is more nuanced than that and that requires some explanation based on scientific principles.” ^[92]

10. Kiran Mazumdar-Shaw – Executive Chairperson of Biocon

Background: Kiran Mazumdar-Shaw is a pioneering biotech entrepreneur from India and a powerful voice for the global biotech industry. She is the founder and Executive Chairperson of Biocon Ltd., which she established in 1978 as a small enzyme manufacturer and grew into India’s leading biopharmaceutical company. With over four decades in biotech, Mazumdar-Shaw has been a trailblazer – one of the first in India to push for biotech innovation and high-quality biosimilars (generic biologic drugs) to make therapies affordable. She has received numerous honors, including being named among TIME magazine’s 100 most influential people in the world ^{[101] [102]}. She also serves on various national and international advisory councils on science and trade, reflecting her standing as a thought leader.

Speaking Topics: Kiran Mazumdar-Shaw speaks passionately about innovation, entrepreneurship, and the potential of biotechnology to solve societal challenges. A recurring theme is her call for innovation-driven value creation in pharma, especially in emerging markets like India. She often points out that while India is a top producer of generic medicines and vaccines by volume, it needs to capture more value through original R&D. “India ranks 14th in terms of value in the global pharma landscape. We need to invest in R&D and foster a culture of intellectual property to capture greater value,” Mazumdar-Shaw urged at a recent industry forum ^[103]. She emphasizes building an innovation ecosystem – bringing government, academia, and industry together – to make India a global bio-innovation hub ^{[104] [105]}. Another focus is entrepreneurship and leadership, especially for women. Mazumdar-Shaw often shares her experience as a “first-generation entrepreneur” overcoming gender and financial hurdles in the 1970s, to inspire young entrepreneurs to persevere in the tech-biotech space ^{[101] [102]}. She also speaks on global health and access, noting that biotech can provide solutions for healthcare and agriculture in developing countries, but it requires visionary investment. Her talks frequently highlight the importance of public policy that supports scientific research, citing her own role in advising the Indian government to implement biotech-friendly policies ^{[106] [107]}.

Notable Engagements: Mazumdar-Shaw remains a sought-after speaker at both Indian and international forums. On December 7, 2025, she was honored with the USC Business Management Award at the inaugural University of Southern California India Awards ^[108]. She has delivered keynote addresses at events like Global Bio-India 2024, where she articulated her vision for India's biotech future ^[104]. In late 2025, she highlighted the transformative potential of AI, quantum computing, and bioengineering, stating "Bioengineering is really the way we have to move forward" to address global challenges in energy, medicine, and climate change ^[109]. She is also a familiar figure at the World Economic Forum and has spoken on global panels about biotechnology's role in sustainable development and how India's API supply chain can shift away from China businesstoday.in.

Influence: In December 2025, Biocon announced plans to fully integrate Biocon Biologics into the parent company in a deal valuing Biocon Biologics at $5.5 billion, creating a unified biopharma powerhouse focused on diabetes, oncology, and immunology ^[110]. The integration is expected to complete by March 31, 2026. Biocon has also appointed four investment banks to raise ₹4,500 crore (~$500 million) to fund strategic initiatives. As of 2025, Mazumdar-Shaw is ranked 93rd-wealthiest in India with a net worth of $3.42 billion, was featured on Forbes' World's 100 Most Powerful Women 2025 list, and ranked 2nd Most Generous Woman on the EdelGive Hurun India Philanthropy List 2025 ^[111]. Her thought leadership continues to push the industry toward a more inclusive, innovation-centric global model, where new medicines are developed with both excellence and affordability in mind.

Notable Quote: “We need to invest in R&D and foster a culture of intellectual property to capture greater value… \ [India] can achieve greater value by nurturing innovation.” ^[103]

---

Conclusion: The pharmaceutical industry in 2025-2026 continues to be propelled forward not just by breakthrough discoveries, but also by the visionary voices of its leaders. The ten figures profiled here – from CEOs navigating post-pandemic market shifts and strategic acquisitions, to Nobel laureates inspiring the next generation, to regulators and advocates shaping policy amid a challenging political landscape – each offer critical insights in their public speaking. This year has seen significant transitions: Emma Walmsley stepped down as GSK CEO, Moderna pivoted toward oncology amid vaccine skepticism, BioNTech acquired CureVac to consolidate mRNA leadership, and major pharmaceutical companies announced tens of billions in U.S. manufacturing investments to navigate tariff concerns and drug pricing negotiations. Their common threads include a dedication to innovation, a commitment to improving patient lives, and an understanding that communication and collaboration are as important as pure scientific prowess. As thought leaders, they don't just represent their organizations; they galvanize the wider community of pharma and biotech professionals. By listening to these speakers, industry professionals and policymakers alike can glean a roadmap for addressing current challenges: whether it's harnessing AI in drug development, navigating evolving vaccine policy, ensuring equitable access to medicines, competing in the obesity drug market, or inspiring the next generation of researchers. The continued influence of these voices will be essential in navigating the complex, fast-evolving landscape of global healthcare.

Sources:

1. UCLA TDG – Albert Bourla LABEST 2023 announcement ^{[4] [1]}

2. BioPharmaDispatch – Bourla on “exclusion epidemic,” Nov. 2023 ^[7]

3. Reuters – Bourla at WEF on drug affordability (fact-check) ^[5]

4. AAE Speakers – Stéphane Bancel Biography ^{[12] [13]}

5. Forbes Healthcare Summit (2024) – Bancel keynote appearances ^[16]

6. Moderna Blog – Bancel’s commencement remarks, May 2023 ^{[112] [20]}

7. Reuters – Bancel Senate hearing on vaccine pricing, Mar. 2023 ^[113]

8. BBC News – Pascal Soriot on no-profit COVID vaccine stance ^{[24] [32]}

9. Columbia Business School Insights – Emma Walmsley on AI, innovation (Nov. 2023) ^{[35] [36]}

10. GSK/FT Event – Walmsley on US healthcare incentives ^{[39] [114]}

11. LinkedIn (V. Narasimhan) – “Future of health” video post (2024) ^{[44] [46]}

12. LinkedIn Transcript – Narasimhan on AI and climate in healthcare ^{[48] [115]}

13. The Guardian – Interview with U. Şahin & O. Türeci (Oct. 2022) ^{[55] [56]}

14. Atlantic Council – Bourla on BioNTech partnership (Nov. 2021) ^[58]

15. Nobel Prize Interview – K. Karikó (Oct. 2023), on perseverance ^[62]

16. Nobel Prize Banquet Speech – Karikó (Dec. 2023), collaboration message ^[68]

17. WWSG Speakers – Scott Gottlieb speech topics ^{[74] [76]}

18. World Medical Innovation Forum – Gottlieb bio/profile (2024) ^[73]

19. Washington Post – Live chat with P. Hotez (July 2023) ^{[88] [87]}

20. Wikipedia – Hotez on misinformation and communication ^[92]

21. Economic Times (India) – Mazumdar-Shaw at Global Bio-India 2024 ^{[116] [103]}

22. London Speaker Bureau – Kiran Mazumdar-Shaw profile ^{[101] [102]}

2025-2026 Update Sources:

23. PharmExec – Pfizer J.P. Morgan 2026 ^[9]

24. BioSpace – Pfizer Metsera acquisition, obesity strategy ^[10]

25. Fortune – Bourla on "scientific renaissance" 2025 ^[11]

26. PharmExec – Moderna J.P. Morgan 2026 ^[18]

27. Boston Globe – Moderna vaccine trial investment 2026 ^[19]

28. BioProcess International – Moderna CEO 2025 shareholder letter ^[21]

29. STAT News – AstraZeneca, Soriot at ASCO 2025 ^[28]

30. Fortune – Soriot on Europe vs. US, Virginia facility 2025 ^[29]

31. BioPharma Dive – Emma Walmsley GSK retirement ^[33]

32. CNBC – GSK CEO transition, Luke Miels named ^[41]

33. Novartis – Vas Narasimhan TIME100 Health 2025 ^[49]

34. CNBC – Novartis tariff deal, Narasimhan at Davos 2026 ^[50]

35. CNBC – Novartis Avidity Biosciences $12B acquisition ^[51]

36. Wikipedia – BioNTech CureVac acquisition June 2025 ^[59]

37. Francis Crick Institute – Uğur Şahin Crick Lecture crick.ac.uk

38. Hungarian Conservative – Karikó 70th birthday, awards 2025 ^[70]

39. University of Szeged – Karikó celebrations 2026 u-szeged.hu

40. MedUni Vienna – Karikó lecture May 2025 meduniwien.ac.at

41. Healthcare Dive – Gottlieb UnitedHealth board Nov 2025 ^[72]

42. The Hill – Gottlieb vaccine schedule concerns Dec 2025 ^[83]

43. Drug Store News – Gottlieb AAM Access! 2026 keynote ^[79]

44. Yale YSPH – Hotez Winslow Medal April 2025 ^[95]

45. PLOS – Hotez antivaccine activism paper 2025 ^[96]

46. U.S. News – Hotez Best Leaders 2025 ^[99]

47. Biocon – Mazumdar-Shaw USC award Dec 2025 ^[108]

48. Business Standard – Biocon Biologics merger Dec 2025 ^[110]